- Home
- PRAX vs LBRDK Comparison
PRAX vs LBRDK Comparison
Compare PRAX & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | LBRDK |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | LBRDK |
|---|---|---|
| Price | $312.49 | $44.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $397.85 | N/A |
| AVG Volume (30 Days) | 616.0K | ★ 1.1M |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.38 |
| EPS | N/A | ★ 5.51 |
| Revenue | $7,463,000.00 | ★ $1,016,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,827.76 | $37.46 |
| P/E Ratio | ★ N/A | $8.02 |
| Revenue Growth | ★ 364.98 | 306.40 |
| 52 Week Low | $26.70 | $43.77 |
| 52 Week High | $326.91 | $104.00 |
Technical Indicators
Market Signals| Indicator | PRAX | LBRDK |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 31.41 |
| Support Level | $266.93 | $47.10 |
| Resistance Level | $306.16 | $49.62 |
| Average True Range (ATR) | 17.82 | 1.53 |
| MACD | -1.32 | -0.40 |
| Stochastic Oscillator | 78.28 | 4.63 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.